ARCHIVES

IDMC Recommends Halting Phase III Trial Of Onartuzumab in MET-Positive NSCLC

This article is from The Cancer Letter archive.

Vol. 37 No. 3 | March 28, 2014

Download PDF Visit The Full Archive

Related Articles

Vaccine Prevented Cervical Pre-Cancers, Non-Invasive Cancers In Phase III Trial

October 28, 2005

Advocates Oppose Proposals to Market Drugs After Phase I.

June 9, 2006

In Brief: Twenty Apply for ICC Director Job, DeVita Says 30 More Centers Needed; PAP Awards To Clark, Fox

March 18, 1983

Cancer Clinical Trials Approved By NCI Last Month Are Listed

November 29, 2002

In Brief: McDonnell Foundation Selects Five For Awards; James Benson Is Named Interim FDA Head

November 24, 1989

Cancer Congress Scientific Program To Update Basic, Clinical Science

April 2, 1982